Merrimack Pharmaceuticals (Preclinical Nanoliposome Programs Assets) is Buildings and Property in United States that focus on Preclinical Nanoliposome program assets business. They cover business area such as preclinical Nanoliposome program asset, Cambridge, Massachusetts.
-
Preclinical Nanoliposome Program Assets
-
One Kendall Square
Suite B7201
Cambridge, MA 02139
United States
Private
preclinical Nanoliposome program assetCambridgeMassachusetts
* We use standard office opening hours in near Merrimack Pharmaceuticals (Preclinical Nanoliposome Programs Assets)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Merrimack Pharmaceuticals (Preclinical Nanoliposome Programs Assets) is Buildings and Property business from United States that founded in - ( years old in ), Merrimack Pharmaceuticals (Preclinical Nanoliposome Programs Assets) business is focusing on Preclinical Nanoliposome Program Assets.
Merrimack Pharmaceuticals (Preclinical Nanoliposome Programs Assets) headquarter office and corporate office address is located in One Kendall Square Suite B7201 Cambridge, MA 02139 United States.
Merrimack Pharmaceuticals (Preclinical Nanoliposome Programs Assets) was founded in United States.
In , Merrimack Pharmaceuticals (Preclinical Nanoliposome Programs Assets) is currently focus on Preclinical Nanoliposome program assets sector.
Above is snippet of Google Trends for "Preclinical Nanoliposome program assets" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Merrimack Pharmaceuticals (Preclinical Nanoliposome Programs Assets), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
